AR040242A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
AR040242A1
AR040242A1 ARP030101961A ARP030101961A AR040242A1 AR 040242 A1 AR040242 A1 AR 040242A1 AR P030101961 A ARP030101961 A AR P030101961A AR P030101961 A ARP030101961 A AR P030101961A AR 040242 A1 AR040242 A1 AR 040242A1
Authority
AR
Argentina
Prior art keywords
composition
hiv
cis
amino
pharmaceutical compositions
Prior art date
Application number
ARP030101961A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR040242A1 publication Critical patent/AR040242A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que comprende (1S,cis)-4-[2-amino-6-(ciclopropilamino)-9H-purin-9-il]-2-ciclopenteno-1-metanol y (2R,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1H)-pirimidin-2-ona en una cantidad que alcanza efectividad antiviral, un vehículo altamente comprimible farmacéuticamente aceptable. Un proceso para la preparación de tal composición, y un método para inhibir el virus de la inmunodeficiencia humana (VIH) el cual comprende administrar tal composición a un paciente infectado con VIH.
ARP030101961A 2002-06-04 2003-06-02 Composiciones farmaceuticas AR040242A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38571702P 2002-06-04 2002-06-04

Publications (1)

Publication Number Publication Date
AR040242A1 true AR040242A1 (es) 2005-03-23

Family

ID=29712206

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101961A AR040242A1 (es) 2002-06-04 2003-06-02 Composiciones farmaceuticas

Country Status (7)

Country Link
US (1) US20050171127A1 (es)
EP (1) EP1513540A1 (es)
JP (1) JP2005532341A (es)
AR (1) AR040242A1 (es)
AU (1) AU2003231955A1 (es)
TW (1) TW200403061A (es)
WO (1) WO2003101467A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
US8568777B2 (en) * 2007-03-30 2013-10-29 Monosol Rx, Llc Packaged film dosage unit containing a complexate
US20120295898A1 (en) 2010-01-27 2012-11-22 Mark Richard Underwood Antiviral Therapy
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US20140234415A1 (en) * 2013-02-20 2014-08-21 Abbvie Inc. Tablet Dosage Forms
RU2705570C1 (ru) * 2018-06-27 2019-11-08 федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации Способ прогнозирования прогрессирующего фиброза печени и выбора комбинации препаратов для антиретровирусной терапии при коинфекции ВИЧ/ВГС

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations

Also Published As

Publication number Publication date
JP2005532341A (ja) 2005-10-27
AU2003231955A1 (en) 2003-12-19
EP1513540A1 (en) 2005-03-16
WO2003101467A1 (en) 2003-12-11
US20050171127A1 (en) 2005-08-04
TW200403061A (en) 2004-03-01

Similar Documents

Publication Publication Date Title
EA000626B3 (ru) Синергические комбинации зидовудина, 1592u89 и зтс или ftc
BG95705A (bg) Аналози на 1,3-оксатиолан нуклеозида
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
PA8588501A1 (es) Derivados antivirales de nucleósidos
AR065970A2 (es) Una composicion farmaceutica oral solida que comprende una combinacion de metformin y glibenclamida y uso de dicha composicion
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
CZ283765B6 (cs) 1,3-Oxathiolannukleosidové analogy
NO20053817L (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR040242A1 (es) Composiciones farmaceuticas
ECSP22081150A (es) Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica
EA200000997A1 (ru) Гомогенные фармацевтические композиции, содержащие абакавир, ламивудин и зидовудин
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
SV1997000090A (es) Composiciones farmaceuticas.
MX2022006940A (es) Composiciones farmaceuticas.
NO970847D0 (no) 2-£amino-6-(cyklopropylamino)-9H-purin-9-yl|-2-cyklopenten-1-metanol-succinat som anti-virusmiddel
AR002957A1 (es) Una combinacion de compuestos utiles, su uso para preparar un medicamento, y una composicion y combinacion farmaceutica que los contienen.
AR023661A1 (es) Combinaciones antivirales
AR005551A1 (es) Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple
AR026255A1 (es) Combinaciones antivirales.
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
AR043332A1 (es) Composiciones y metodos para terapia antiviral
PE20030732A1 (es) Empleo de alquilfosfocolinas en el tratamiento preventivo de enfermedades causadas por protozoarios
ECSP972294A (es) Composiciones farmaceuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure